🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against superbug strains of the pathogen, according to scientists.

An International Public Health Issue

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Receive Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This approval signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Results and Global Access

As per data detailed in a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This places it at an similar efficacy with the typical regimen, which combines an injection and a pill. The study included nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced hope. The availability of a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea globally.